CVS Pharmacy · Financial & Corporate
Active Capital Allocation and Strategic M&A in FY2025
StableSteadyLast updated: 31 December 2025
Retail Brands summary
In FY2025, CVS Health allocated $2.8 billion to capital expenditures and engaged in strategic M&A activities, including $436 million in acquisitions and a $483 million gain from the deconsolidation of Omnicare, while opting against share buybacks and maintaining quarterly dividends.
Key facts
- Brand
- CVS Pharmacy
- Signal category
- Financial & Corporate
- Current status
- Stable
- Direction
- Steady
- Importance
- High
- Scope
- Global
- Sources
- 1 (cvs-20251231)
- Last updated
- 31 December 2025
More CVS Pharmacy Financial & Corporate signals
- Robust Financial Performance and Shareholder Value Creation in FY2025Financial & Corporate · Increasing · 29 September 2026
CVS Health demonstrated strong financial performance in FY2025 with 7.8% revenue growth, improved Medical Benefit Ratio, and significant operating cash flow, contributing to a 12.4% stock price increase and consistent…
- Financial Settlement for Website Tracking LitigationFinancial & Corporate · One off · 25 September 2026
CVS Health agreed to a $20.5 million settlement to resolve litigation related to website tracking, incurring a direct financial cost.
- Strategic Optimization of Physical Retail Footprint with Net Store Closures in FY2025Financial & Corporate · Increasing · 31 December 2025
CVS Health strategically reduced its physical retail footprint in FY2025 by closing 243 locations while opening 87 new ones, resulting in a net decrease of 156 stores, aligning with its broader strategy to simplify…
- Significant Financial Liabilities from Debt and LeasesFinancial & Corporate · Stable · 31 December 2025
As of the end of FY2025, CVS Health reported substantial financial obligations, including $64.57 billion in long-term debt and $15.38 billion in operating lease liabilities.